| Jetquatta Parker, LPN | |
|
786 Coates St, Coatesville, PA 19320 | |
| (484) 378-1816 | |
| Not Available |
| Full Name | Jetquatta Parker |
|---|---|
| Gender | Female |
| Speciality | In Home Supportive Care |
| Location | 786 Coates St, Coatesville, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528540499 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Jetquatta Parker, LPN 786 Coates St, Coatesville, PA 19320-3370 Ph: (484) 378-1816 | Jetquatta Parker, LPN 786 Coates St, Coatesville, PA 19320 Ph: (484) 378-1816 |
News Archive
Health News Florida: "In a surprising turnaround from last week, a top Senate health chairman Monday called off two meetings that had been scheduled to scrutinize a House proposal for overhauling the Medicaid system. The Senate Health Regulation Committee planned to hold more than nine hours of meetings Wednesday and Thursday to study House bills that would require almost all Medicaid recipients to move into managed-care plans.
A new study by American Cancer Society researchers finds medical financial hardship is very common among people in the United States, with more than half reporting problems with affordability, stress, or delaying care because of cost.
It's a natural laboratory for studying heart disease, lung problems, muscle loss, sleeping disorders and new medical technologies. It's also the highest mountain in the world. Mount Everest's extreme altitude puts climbers under the same conditions experienced by patients suffering from heart disease, obesity or advanced age. To take advantage of that, Mayo Clinic researchers are joining an expedition to Everest with National Geographic, The North Face and Montana State University.
Eli Lilly and Company will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.
› Verified 1 days ago